Magnetic Resonance Imaging-guided Transurethral Ultrasound Ablation (TULSA) of Localized Prostate Cancer: A prospective Trial
Journal of Vascular and Interventional Radiology · 2025-09 · 36 (9) · 1401-1408
DOI: 10.1016/j.jvir.2025.05.024 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Journal of Vascular and Interventional Radiology, 2025-09. Verfasst von Thibault Tricard und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Nouvel Hôpital Civil, CHRU Strasbourg, Strasbourg, France; ICube UMR 7357, Illkirch, France. Electronic address: thibault.tric…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Magnetic Resonance Imaging, Interventional, High-Intensity Focused Ultrasound Ablation. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 13 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: To evaluate the effectiveness and safety of the TULSA-PRO device in treating organ-confined low-risk to intermediate-risk prostate cancer (PCa). MATERIALS AND METHODS: This prospective, single-center clinical trial included 25 men with organ-confined low-risk/intermediate-risk PCa (prostate-specific antigen ≤ 15 ng/mL, International Society of Urological Pathology ≤ 2, magnetic resonance [MR] imaging ≤ iT2c). Patients underwent MR imaging-guided focused ultrasound treatment, followed by clinical reevaluation at 1, 3, 6, and 12 months. The primary end point was the absence of clinically significant cancer (CSC) on the 12-month systematic and targeted biopsy. Secondary end points included safety, quality of life, prostate-specific antigen variation, and functional outcomes. RESULTS: At 12 months, 43.5% of patients (10/23) had CSC on biopsy, with a recurrence-free survival rate of 40% and a treatment-free survival rate of 72% after a median follow-up of 37 months (range, 14-54 months). Functional outcomes revealed stress urinary incontinence in 6 patients, overactive bladder in 8, and severe erectile dysfunction in 7 of the 13 preprocedurally potent patients. Otherwise, the safety profile was favorable, with no severe adverse event related to the treatment. MR imaging follow-up detected suspicious lesions in 3 of the 10 (30%) patients with CSC at 12 months. CONCLUSIONS: Transurethral ultrasound ablation shows promise as a focal treatment for localized PCa, although it may not be universally curative. Continued surveillance and further studies are required to assess long-term effectiveness and to optimize functional outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Urology, Nouvel Hôpital Civil, CHRU Strasbourg, Strasbourg, France; ICube UMR 7357, Illkirch, France. Electronic address: thibault.tricard@chru-strasbourg.fr.
- ICube UMR 7357 - Laboratoire des sciences de l'ingénieur, de l'informatique et de l'imagerie 300 bd Sébastien Brant -67412 Illkirch.
- Department of Urology, Nouvel Hôpital Civil, CHRU Strasbourg, Strasbourg, France.
- ICube UMR 7357, Illkirch, France.
- Pôle Santé Publique, Hôpitaux Universitaires de Strasbourg, France.
Zitieren
APA
Tricard, T., Cazzato, R. L., Schroeder, A., De Mathelin, M., Barhoumi, C., Gaillard, V., Sauleau, E., Gangi, A., & Lang, H. (2025). Magnetic Resonance Imaging-guided Transurethral Ultrasound Ablation (TULSA) of Localized Prostate Cancer: A prospective Trial. Journal of Vascular and Interventional Radiology, 36(9), 1401-1408. https://doi.org/10.1016/j.jvir.2025.05.024
Vancouver
Tricard T, Cazzato RL, Schroeder A, De Mathelin M, Barhoumi C, Gaillard V, et al. Magnetic Resonance Imaging-guided Transurethral Ultrasound Ablation (TULSA) of Localized Prostate Cancer: A prospective Trial. Journal of Vascular and Interventional Radiology. 2025;36(9):1401-1408. doi:10.1016/j.jvir.2025.05.024
BibTeX
@article{Tricard2025,
author = {Tricard, Thibault and Cazzato, Roberto Luigi and Schroeder, Alice and De Mathelin, Michel and Barhoumi, Clara and Gaillard, Victor and Sauleau, Erik and Gangi, Afshin and Lang, Hervé},
title = {Magnetic Resonance Imaging-guided Transurethral Ultrasound Ablation (TULSA) of Localized Prostate Cancer: A prospective Trial},
journal = {Journal of Vascular and Interventional Radiology},
year = {2025},
volume = {36},
number = {9},
pages = {1401--1408},
doi = {10.1016/j.jvir.2025.05.024}
}
EUVIMED